David Rice (CYH) receives restricted stock, options and performance shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
COMMUNITY HEALTH SYSTEMS INC reported that EVP-Clinical Operations & CMO David V. Rice received several equity awards as compensation. He was granted 30,000 shares of common stock that vest in one-third increments on the first, second and third anniversaries of the June 1, 2026 grant date, giving him 30,000 common shares directly following this grant.
He was also granted 30,000 stock options with a $2.75 per share exercise price, expiring on May 31, 2036, covering 30,000 underlying common shares and vesting in one-third increments on the first three anniversaries of the grant date. In addition, he received 30,000 performance-based restricted shares, with the target number tied 50% to a Cumulative Same-Store Adjusted EBITDA Growth objective and 50% to a Cumulative Same-Store Net Revenue Growth objective over the 2026–2028 Performance Period. Between 0% and 200% of the target tied to each objective may ultimately vest on March 1, 2029, depending on actual performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Rice David V.
Role
EVP-Clinical Operations & CMO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance Based Restricted | 30,000 | $0.00 | -- |
| Grant/Award | Stock Options (Right to Buy) | 30,000 | $0.00 | -- |
| Grant/Award | Common Stock | 30,000 | $0.00 | -- |
Holdings After Transaction:
Performance Based Restricted — 30,000 shares (Direct, null);
Stock Options (Right to Buy) — 30,000 shares (Direct, null);
Common Stock — 30,000 shares (Direct, null)
Footnotes (1)
- The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. The vesting of these performance-based restricted shares is allocated to the Issuer's attainment of the following predetermined performance objectives between 1/1/2026 and 12/31/2028 (the "2026-2028 Performance Period"), as follows: 50% to a Cumulative Same-Store Adjusted EBITDA Growth target; and 50% to a Cumulative Same-Store Net Revenue Growth target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on 3/1/2029, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2026-2028 Performance Period. Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.
Key Figures
Restricted stock grant: 30,000 shares
Options granted: 30,000 options
Option exercise price: $2.75 per share
+5 more
8 metrics
Restricted stock grant
30,000 shares
Time-based restricted common stock granted June 1, 2026
Options granted
30,000 options
Stock Options (Right to Buy) granted June 1, 2026
Option exercise price
$2.75 per share
Conversion or exercise price for 30,000 stock options
Option expiration
May 31, 2036
Expiration date of stock options grant
Performance-based shares
30,000 shares
Target number of performance-based restricted shares
Service-based vesting schedule
1/3 per year over 3 years
Applies to restricted stock and options from grant date
Performance period
2026–2028
For performance-based restricted shares metrics
Performance vesting range
0% to 200%
Portion of target performance-based shares that may vest
Key Terms
performance-based restricted shares, Cumulative Same-Store Adjusted EBITDA Growth, Cumulative Same-Store Net Revenue Growth, 2026-2028 Performance Period, +1 more
5 terms
Cumulative Same-Store Adjusted EBITDA Growth financial
"50% to a Cumulative Same-Store Adjusted EBITDA Growth target..."
Cumulative Same-Store Net Revenue Growth financial
"50% to a Cumulative Same-Store Net Revenue Growth target."
2026-2028 Performance Period financial
"during the 2026-2028 Performance Period."
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy)"
FAQ
What equity awards did CYH grant to David V. Rice in this Form 4?
COMMUNITY HEALTH SYSTEMS INC granted David V. Rice 30,000 restricted common shares, 30,000 stock options, and 30,000 performance-based restricted shares as compensation, all dated June 1, 2026, with multi‑year vesting tied to time and financial performance.
How do David V. Rice’s CYH restricted stock awards vest?
The time-based restricted common shares vest in one-third increments on the first, second, and third anniversaries of the June 1, 2026 grant date, gradually delivering 30,000 CYH shares to David V. Rice over three years if he continues to meet service conditions.
What are the terms of the CYH stock options granted to David V. Rice?
David V. Rice received 30,000 CYH stock options at a $2.75 exercise price per share, expiring May 31, 2036. These options relate to 30,000 underlying common shares and vest in one-third increments on each of the first three anniversaries of the grant date.
Are David V. Rice’s CYH equity awards open-market purchases or compensation grants?
The CYH Form 4 shows compensation-related grants, not open-market purchases. All three transactions use code A, indicating grant or award acquisitions with a zero transaction price per share, reflecting equity-based compensation rather than market trading activity.